A director at Green Brick Partners Inc sold 35,000 shares at 67.617USD and the significance rating of the trade was 71/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two year...
HCI Group Reports Second Quarter 2025 Results Second Quarter Pre-Tax Income of $94.4 million and Diluted EPS of $5.18Book Value Per Share Increased to $58.55Gross Loss Ratio of 21.3% TAMPA, Fla., Aug. 07, 2025 (GLOBE NEWSWIRE) -- HCI Group, Inc. (NYSE:HCI), reported pre-tax income of $94.4 million and net income of $70.3 million for the second quarter of 2025. Net income after noncontrolling interests was $66.2 million compared with $54.1 million in the second quarter of 2024. Diluted earnings per share were $5.18 in the second quarter of 2025, compared with $4.24 in the second quart...
Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results CLN-978 program now actively enrolling across Phase 1 studies in systemic lupus erythematosus (SLE), rheumatoid arthritis (RA) and Sjögren’s disease BCMA-directed bispecific T cell engager velinotamig in-licensed from Genrix Bio Zipalertinib REZILIENT1 pivotal results shared in oral presentation at ASCO 2025 and in Journal of Clinical Oncology; multiple new data sets across a range of disease settings to be shared at IASLC 2025 WCLC and ESMO Congress 2025 Company appoints Mittie Doyle, M.D.,...
HCI Group Sets Second Quarter 2025 Earnings Call for Thursday, August 7, 2025, at 4:45 p.m. ET TAMPA, Fla., July 14, 2025 (GLOBE NEWSWIRE) -- (NYSE: HCI) will hold a conference call on Thursday, August 7, 2025, at 4:45 p.m. Eastern Time to discuss results for the second quarter ended June 30, 2025. Financial results will be issued in a press release the same day after the close of the market. HCI management will host the presentation, followed by a question-and-answer period. Interested parties can listen to the live presentation by dialing the listen-only number below or by clicking t...
HCI Group Declares Quarterly Cash Dividend TAMPA, Fla., July 02, 2025 (GLOBE NEWSWIRE) -- The board of directors of (NYSE: HCI) has declared a regular quarterly cash dividend in the amount of 40 cents per common share. The dividend is scheduled to be paid September 19, 2025 to shareholders of record at the close of business August 15, 2025. About HCI Group, Inc.HCI Group is a holding company with two distinct operating units. The first unit includes four top-performing insurance companies, a captive reinsurance company, and operations in claims management and real estate. The second uni...
Cullinan Therapeutics Licenses Rights to Velinotamig, a Clinical-Stage BCMA-Directed Bispecific T Cell Engager, from Genrix Bio for Development in Autoimmune Diseases Advances Cullinan’s leadership in T cell engager (TCE) development for autoimmune diseases with both a CD19 TCE and BCMA TCE in its pipeline Strengthens Cullinan portfolio of autoimmune programs with the opportunity to address a broader range of diseases while maintaining cash runway into 2028 Company to host conference call today at 4:30 pm ET CAMBRIDGE, Mass., June 04, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: CGEM; “Cullinan”...
HCI Group Announces Completion of its 2025 – 2026 Catastrophe Reinsurance Programs TAMPA, Fla., June 02, 2025 (GLOBE NEWSWIRE) -- (NYSE: HCI) has successfully completed its catastrophe reinsurance programs for the 2025-2026 treaty year, which runs from June 1, 2025 through May 31, 2026. “We are grateful for the strong support from our global reinsurance partners, whose continued confidence in HCI underscores the quality of our underwriting and our disciplined approach to risk,” said Paresh Patel, HCI’s chairman and chief executive officer. “We believe our reinsurance programs are pruden...
Cullinan Therapeutics to Host Analyst and Investor Event at 2025 ASCO Annual Meeting and Participate in Jefferies 2025 Global Healthcare Conference CAMBRIDGE, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: CGEM; “Cullinan”), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today announced its management team will host a company event at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL and will participate in the Jefferies 2025 Global Healthcare Conference, being held June 3-5, 2025 in New York, NY. The Company w...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.